Top

Published in:

01-10-2011 | PRECLINICAL STUDIES

Liquid crystal-related compound-induced cell growth suppression and apoptosis in the chronic myelogenous leukemia K562 cell line

Authors: Yukako Fukushi, Masaharu Hazawa, Kenji Takahashi, Atsushi Yoshizawa, Ikuo Kashiwakura

Published in: Investigational New Drugs | Issue 5/2011

Summary

Liquid crystals are the state of matter existing between the liquid and the crystalline phase, and there is a recent surging interest in its biological effects. Our previous study showed that liquid crystal-related compounds (LCRCs), which are precursors of the liquid crystal, enhanced hematopoietic differentiation at a relatively low concentration (Biol Pharm Bull, 32, 2009). However, biological potentials of LCRCs on tumor cells are unclear. In this study, the biological activity of 16 LCRCs to a chronic myelogenous leukemia cell line, K562, was evaluated. As a result, two compounds, 2-(4-butoxyphenyl)-5-(4-hydroxyphenyl)pyrimidine (compound 7) and 2-{4-(4-hexyloxyphenyl)phenyl}-5-hydroxypyrimidine (compound 9) showed marked growth suppression of K562 cells at μM range. These compounds are similar in structure with a core of three aromatic rings including a pyrimidine ring and residues of one alkyl chain and one hydroxide on either side. In addition, only compound 7 induced the activation of p38 mitogen-activated protein kinase and c-Jun N-terminal kinase, and apoptosis of K562 cells. The contrasting results between compounds 7 and 9 indicate different mechanisms to suppress the cell proliferation between the two compounds. These results suggest the possibility of LCRCs for application as new antitumor drugs.

Uga H, Kuramori C, Ohta A, Tsuboi Y, Tanaka H, Hatakeyama M, Yamaguchi Y, Takahashi T, Kizaki M, Hanada H (2006) A new mechanism of methotrexate action revealed by target screening with affinity beads. Mol Pharm 70:1832–1839CrossRef

Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev 7:573–584CrossRef

Wang SY, Weiner G (2008) Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther 8:759–768PubMedCrossRef

Perez EA (2009) Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 8:2086–2095PubMedCrossRef

Metzger-Filho O, Moulin C, De Azambuja E, Ahamad A (2009) Larotaxel: broadening the road with new taxanes. Expert Opin Investig Drugs 18:1183–1189PubMedCrossRef

Skobridis K, Kinigopoulou M, Theodorou V, Giannousi E, Russell A, Chauhan R, Sala R, Brownlow N, Kiriakdis S, Domin J, Tzakos AG, Dibb NJ (2010) Novel imatinib derivatives with altered specificity between bcr-abl and FMS, KIT, and PDGF receptors. Chem Med Chem 5:130–139PubMed

Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T (1994) Bcr-Abl oncoproteins bind directly to activators of the Ras signaling pathway. EMBO J 13:764–773PubMed

Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B (1997) Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 16:6151–6161PubMedCrossRef

Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038–1042PubMedCrossRef

10.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, WT WE, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug reasistance. Biochim Biophys Acta 1773:1263–1284PubMedCrossRef

11.

Fava C, Kantarjian H, Cortes J, Jabbour E (2008) Development and targeted use of nilotinib in chronic myeloid leukemia. Drug Des Devel Ther 2:223–243

12.

Hazlehurst LA, Bewry NN, Nair RR, Pinilla-lbarz J (2009) Signaling networks associated with bcr-abl-dependent transformation. Cancer Control 16:100–107PubMed

13.

Hochhaus A, Schenk T, Erben P, Ernst T, Rosée P, Müller M (2009) Cause and management of therapy resistance. Best Pract Res Clin Haematol 22:577–582CrossRef

14.

Stevenson CL, Bennet DB, Lechuga-Ballesteros D (2005) Pharmaceutical liquid crystals: the relevance of partially ordered systems. J Pharm Sci 94:1861–1880PubMedCrossRef

15.

Dymond MK, Attard GS (2008) Cationic Type І amphiphiles as modulators of membrane curvature elastic stress in vivo. Langmuir 24:11743–11751PubMedCrossRef

16.

Terasawa R, Fukushi Y, Monzen S, Miura T, Takahashi K, Yoshizawa A, Kashiwakura I (2009) The promoting activity on human megakaryocytopoiesis and thrombopoiesis by liquid crystal-related compounds. Biol Pharm Bull 32:976–981PubMedCrossRef

17.

Hazawa M, Wada K, Takahashi K, Mori T, Kawahara N, Kashiwakura I (2009) Suppressive effects of novel derivatives prepared from aconitum alkaloids on tumor growth. Invest New Drugs 27:111–119PubMedCrossRef

18.

Kirk KL (2006) Selective fluorination in drug design and development: an overview of biochemical rationales. Curr Top Med Chem 6:1447–1456PubMedCrossRef

19.

Crocker PJ, Mahadevan A, Wiley JL, Martin BR, Razdan RK (2007) The role of fluorine substitution in the structure–activity relationships (SAR) of classical cannabinoids. Bioorg Med Chem Lett 17:1504–1507PubMedCrossRef

20.

Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinase on apoptosis. Science 270:1326–1331PubMedCrossRef

21.

Zhang G, Fu Y (2006) Antiproliferative effect of indomethacin on CML cells is related to the suppression of STATs/Bcl-xL signal pathway. Ann Hematol 85:443–449PubMedCrossRef

22.

Yang SH, Chien CM, Lu MC, Lin YH, Hu XW, Lin SR (2006) Up-regulation of Bax and endonuclease G, and down-modulation of Bcl-xL involved in cardiotoxin III-induced apoptosis in K562 cells. Exp Mol Med 38:435–444PubMed

23.

Meng Y, Li Y, Li J, Li H, Fu J, Liu Y, Liu H, Chen X (2007) (-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells. Leuk Lymphoma 48:2204–2212PubMedCrossRef

24.

Liu MJ, Li HX, Wu RC, Liu YZ, Wu QY (2004) Mitochondrial dysfunction as an early event in the process of apoptosis induced by woodfordin Iin human leukemia K562 cells. Toxicol Appl Pharm 194:141–155CrossRef

25.

Mao X, Yu CR, Li WH, Li WX (2008) Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells. Cell Res 18:879–888PubMedCrossRef

26.

Yoshizawa A, Takahashi Y, Terasawa R, Shota C, Takahashi K, Haawa M, Kashiwakura I (2009) Liquid crystallinity and biological activity of a novel amphiphilic compound. Chem Lett 38:310–311CrossRef

27.

Yoshizawa A, Takahashi Y, Terasawa R, Shota C, Takahashi K, Haawa M, Kashiwakura I (2009) Biological activity of some cyanobiphenyl derivatives. Chem Lett 38:530–531CrossRef

Title: Liquid crystal-related compound-induced cell growth suppression and apoptosis in the chronic myelogenous leukemia K562 cell line
Authors: Yukako Fukushi
Masaharu Hazawa
Kenji Takahashi
Atsushi Yoshizawa
Ikuo Kashiwakura
Publication date: 01-10-2011
Publisher: Springer US
Published in: Investigational New Drugs / Issue 5/2011
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-010-9430-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 5/2011

Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer

Kit inhibitor APcK110 extends survival in an AML xenograft mouse model

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)

The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity

Ultraviolet recall dermatitis reaction with sorafenib

Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor

Keynote webinar | Spotlight on antibody–drug conjugates in cancer